DGAP-News

Gerresheimer AG: Gerresheimer with positive start to the financial year 2021 - Seite 2

The Company continued to expand its production capacities for manufacturing injection vials for Covid-19 vaccines in the first quarter of 2021. By doing so, the Company is reaffirming its responsibility and making an important contribution to combating the pandemic by supplying glass vials to be filled with vaccines.

Adjusted EBITDA stood at EUR 54m in the first quarter of 2021. In the core business, adjusted EBITDA rose organically by 7.0% year on year to EUR 57m. The adjusted EBITDA margin in the core business amounted to 19.0%. The adjusted net income was EUR 18m, resulting in adjusted earnings per share of EUR 0.57 with an increase of organically 29.3% (32.6 % as reported) compared to the same quarter in the prior year.

Forecast

Outlook for the financial year 2021 (core business, currency-adjusted):

- Revenues growth in the mid single-digit percentage range

- Adjusted EBITDA margin between 22% and 23%

- Adjusted earnings per share in euros to increase by at least 10%

 

Medium term (core business, net of currency effects):

- Revenues growth in the high single-digit percentage range

- Adjusted EBITDA margin of around 23%

- Adjusted earnings per share in euros to increase by at least 10% per year

The Quarterly Statement for the first quarter of 2021 is available here:
https://www.gerresheimer.com/en/company/investor-relations/reports

Press contact
Jens Kürten
Group Senior Director Communication & Marketing
T [phone]
[e-mail]

Investor Relations contact
Carolin Nadilo
Corporate Director Investor Relations
T [phone]
[e-mail]

 

About Gerresheimer
Gerresheimer is the global partner for pharma, biotech, healthcare and cosmetics with a very broad product range for pharmaceutical and cosmetic packaging and drug delivery devices. The company is an innovative solution provider from concept to delivery of the end product. Gerresheimer achieves its ambitious goals through a high level of innovative strength, industrial competence, focus on quality and customers. In developing innovative and sustainable solutions, Gerresheimer relies on a comprehensive international network with numerous innovation and production centers in Europe, America and Asia. Gerresheimer produces close to its customers worldwide with around 10,000 employees and generates annual sales of more than €1.4 billion. With its products and solutions, Gerresheimer plays an essential role in people's health and well-being.